04/03/2005
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’), a company whose product Colostrinin has shown efficacy as a potential treatment for Alzheimer’s disease, announces that a patent on the use of Colostrinin as a treatment for dementia, including Alzheimer’s disease, has been granted by the United States Patent and Trademark Office.
The grant of this patent adds further strength to the intellectual property portfolio owned by or licensed to ReGen. ReGen presently holds rights to eleven other patents issued since 2000 relating to the use of Colostrinin. The Company has filed a number of other patent applications in relation to Colostrinin its constituent peptides and analogues and these are currently being evaluated by the relevant patent authorities.
Commenting on the latest patent grant in the US, Chairman Percy Lomax said ‘ We now have a patent covering the use of Colostrinin as a treatment for dementia, including Alzheimer’s disease, in the largest Pharmaceutical and most developed Nutraceutical market in the world. This is a very significant step commercially and adds strength to our negotiations with business partners.’
For further information, please contact:
Andrew Marshall
Marshall Robinson roe
Tel No 020 7960 6007